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Abstract
Background: Precise assessment of health-related quality of life (HRQOL) with a reliable and valid measure is a
prerequisite to the enhancement of HRQOL. This study examined the psychometric properties of the Korean
version of the Medical Outcomes Study HIV Health Survey (K-MOS-HIV).
Methods: The reliability and validity of the K-MOS-HIV were examined in a multicenter survey involving 201
outpatients with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) from four
teaching hospitals throughout Korea.
Results: Ceiling effects were observed in six subscales scores, particularly, for the role functioning (71.1%), social
functioning (63.2%), and pain (48.8%) scores. The Cronbach’s α for the physical health summary and mental
health summary were 0.90 and 0.94, respectively, and it ranged from 0.78 to 0.95 for the subscales. The results of
the exploratory structural equation modeling supported the two-factor structure of the K-MOS-HIV (physical health
summary and mental health summary). An examination of the mean square statistics values from the Rasch analysis
showed that the information-weighted fit and outlier-sensitive fit statistics were within the acceptable ranges of 0.6–1.4
except for two items in the mental health summary. The convergent validity of the K-MOS-HIV was supported by its
significant positive correlations with the World Health Organization Quality of Life-HIV-BREF subscale scores. Its known-
group validity was proven with its ability to detect significant differences in several K-MOS-HIV subscale scores among
participants with different sociodemographic and clinical characteristics.
Conclusions: The K-MOS-HIV health survey appears to be a reliable and valid measure of HRQOL.
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Background
As of 2015, 36.7 million persons are living with human
immunodeficiency virus (HIV) worldwide [1]. With pro-
gress in treatment such as the introduction of highly ac-
tive antiretroviral therapy (HAART), HIV has become a
chronic illness with a significant decrease in HIV-related
morbidity and mortality [2].
However, HIV/ acquired immunodeficiency syndrome
(AIDS) still negatively affects the health-related quality
of life (HRQOL) in people with HIV and AIDS
(PLWHA) [3, 4]. HRQOL in PLWHA was significantly
lower as compared to that of the general population [3]
and those with other chronic diseases [5]. The stigma as-
sociated with HIV/AIDS is one worsening factor affect-
ing HRQOL [6, 7]. Moreover, according to a prospective
cohort study, HRQOL, particularly physical QOL, was a
prognostic factor of survival among persons with HIV
[8]. As such, attention to HRQOL-related issues and
clinical efforts to enhance HRQOL in PLWHA are war-
ranted. The precise assessment of HRQOL with a reli-
able and valid measure is a prerequisite to improve
HRQOL. The World Health Organization Quality of
Life-HIV-BREF (WHOQOL-HIV BREF) [9], Functional
Assessment of HIV infection quality of life instrument
(FAHI) [10], and the Medical Outcomes Study HIV
Health Survey (MOS-HIV) [11] are some of the HIV/
AIDS-specific tools that are used widely to assess the
HRQOL of PLWHA. In particular, the FAHI and MOS-
HIV are considered two of the most appropriate HIV-
targeted HRQOL measures [12].
Among them, the application of the MOS-HIV to as-
sess HRQOL is useful in two ways. Firstly, it allows
between-group comparisons (e.g., populations with other
diseases and healthy populations) as the MOS-HIV was
developed from generic MOS instruments. It also per-
mits within-group and cross-cultural comparisons as it
has been applied to PLWHA worldwide, enabling the
use of a vast amount of accumulated data for such com-
parisons [13]. The feasibility of the use of the MOS-HIV
has been proven [14, 15], and it has been validated in
several languages such as Chinese [16, 17], French [18],
German [18], Greek [19], Italian [20, 21], Spanish [14],
Thai [22] and Luganda [23].
The number of PLWHA in South Korea is increasing
consistently, with an average of 1000 new cases reported
each year since 2011. As of 2016, the number of
PLWHA was 11,439 [24]. However, research regarding
HRQOL in Korean PLWHA is limited. The strong
stigma associated with the disease is prominent in
Korea, as is the lack of a standardized and valid HRQOL
tool. These seem to be some of the reasons behind this
paucity of HRQOL research on the Korean population.
Until now, only the WHOQOL-HIV BREF [25] has been
translated and validated in Korean, and there is no
validated Korean version of the MOS-HIV health survey.
Thus, the purpose of the present study was to examine
the psychometric properties of the Korean version of the
MOS-HIV health survey in a sample of PLWHA in Korea.
Methods
Participants and procedures
Participants consisted of 201 outpatients with HIV/AIDS
recruited via consecutive sampling. This cross-sectional,
multi-center survey implemented between December
2016 and June 2017 involved four university hospitals in
South Korea (two located in Seoul, the capital city, and
the other two in the cities of Seongnam and Busan). On
the provision of informed consent, the participants were
asked to complete the survey, and they could complete
it either on site or take it home and return it by mail. A
gift certificate (equivalent to $9 U.S. dollars) was pro-
vided as a reward to all participants. This study was ap-
proved by the respective Institutional Review Boards of
the participating institutions.
Measures
The MOS- HIV, developed by Albert Wu and col-
leagues, is a self-report measure to assess HRQOL for
patients with HIV/AIDS [26]. It has 35 items evaluating
the following 11 dimensions of HRQOL: general health
perception; pain; physical functioning; role functioning;
social functioning; energy/fatigue; mental health; health
distress; cognitive functioning; quality of life; and health
transition. It also provides two summary scores of phys-
ical health and mental health, calculated from the scores
of 10 subscales, excluding the health transition subscale
[27]. While the scores on the physical functioning, pain,
and role functioning scores contribute more strongly to
the physical health summary score, those on mental
health, health distress, quality of life, and cognitive func-
tioning contribute more strongly to the mental health
summary score. Scores on general health perception, en-
ergy/fatigue, and social functioning contribute to both fac-
tors [27]. Respondents rate items on a three-, five- and
six-point Likert scale, and on a dichotomous yes/no scale,
with reference to the last 4 weeks. In accordance with the
MOS-HIV scoring instructions [28], the 11 items are
recoded, and subscale scores as well as the two summary
scores are computed. The MOS-HIV scores range from 0
to 100, with higher scores indicating better HRQOL.
The Korean version of the MOS-HIV (K-MOS-HIV)
underwent a forward-backward translation procedure
according to the European Organization for the Re-
search and Treatment of Cancer translation guidelines
[29]. Forward translation was performed by two inde-
pendent clinicians, and the two versions of the Korean
translation were integrated into a single version that
underwent back-translation by an English speaker who
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has a good command of the Korean language and was
blinded to the original version of the MOS-HIV. The de-
veloper of the MOS-HIV examined the back-translated
version of the MOS-HIV and confirmed structural and
semantic equivalence.
Moreover, the Korean version of the World Health
Organization Quality of Life-HIV-BREF (K-WHOQOL-
HIV BREF) [9, 25] was used as a criterion measure to
determine the convergent validity of the K-MOS-HIV.
The WHOQOL-HIV BREF has 31 items with 29 items
divided into six domains of HRQOL in PLWHA (i.e.,
physical QOL, psychological QOL, level of independ-
ence, social relationships, environment, and spiritual
QOL) and two items assessing an individual’s overall
perception of QOL and health, respectively. Items are
rated on a five-point Liker scale, and six domain scores
are computed in accordance with the scoring guidelines
[30]. Domain scores range from 4 to 20, with higher
scores denoting higher QOL. The Cronbach’s α of the K-
WHOQOL-HIV BREF is 0.94 [25].
Questions regarding sociodemographic data (i.e., age,
sex, education, marital status, religion, employment, in-
come, and insurance status) were included in a self-report
survey. Clinical information (i.e., the Center for Disease
Control and Prevention stage, years since diagnosis, CD4
cell counts, HIV RNA log, active antiretroviral therapy
(ART) duration, psychological comorbidity, and medical
comorbidity) were retrieved from medical records. A
question regarding mode of transmission was also in-
cluded in the survey, and participants were asked to
choose among the options of sex with a person of the op-
posite sex, sex with a person of the same sex, and others.
Statistical analyses
To determine whether the scale had adequate range
variability, the floor and ceiling effects of the K-MOS-
HIV were evaluated by examining percentages of scores
at the extremes of the scaling range [19, 31].
The construct validity of the K-MOS-HIV was deter-
mined by examining its factorial and convergent validity.
To determine its factorial validity, a confirmatory factor
analysis (CFA) and exploratory structural equation mod-
eling (ESEM) for a two-factor structure (physical health
summary and mental health summary) were performed.
In clinical research, many clinical symptoms or associ-
ated characteristics are likely to be associated with each
other [32]. Therefore, the CFA, which requires the re-
striction of zero cross-loadings, might be restrictive,
resulting in biased estimates [32, 33]. The ESEM, which
is an integration of the best aspects of CFA, structural
equation modeling, and exploratory factor analysis, does
not require a strict restriction of zero cross-loading that
causes over-estimated factor correlations and subsequent
distorted structural relations [34]. Therefore, the model-
fit of the CFA and ESEM for a two-factor structure was
evaluated. The following criteria were applied to evaluate
the goodness-of-fit indices of the factor models: stan-
dardized root mean square residual (SRMR) ≤ .08, com-
parative fit index (CFI) ≥ .95, Tucker-Lewis Index (TLI)
≥ .95, root mean square error of approximation
(RMSEA) ≤ .08, and 90% confidence interval (CI) of
RMSEA [35]. The factorial validity of the K-MOS-HIV
was also examined by testing the partial credit model
(PCM) in the polytomous model of a Rasch analysis
[36]. The PCM is considered to be appropriate for ana-
lyzing responses in attitude or personality scales in
which respondents rate their beliefs, or respond to state-
ments on a multi-point scale [37]. The Rasch analysis
provides two mean square (MNSQ) statistics, the
outlier-sensitive fit statistic (outfit) and information-
weighted fit statistic (infit) MNSQ. The outfit MNSQ is
sensitive to outlier observations in the data, whereas the
infit MNSQ is sensitive to unexpected inlying patterns
among non-outlier observations. Therefore, the infit and
outfit statistics were used to determine whether the item
responses fit the expectations of the PCM. Both item
MNSQ values of about 1.0 are considered ideal, and the
values between 0.6 to 1.4 are deemed acceptable [38].
Higher MNSQ values (e.g., > 1.4) indicate a lack of con-
struct homogeneity with other items in a scale, while
lower values (e.g., < 0.6) indicate potential redundancy of
the item with the rest of the scale [38, 39].
The convergent validity of the K-MOS-HIV was exam-
ined by examining its correlations with the K-
WHOQOL-HIV BREF subscales scores. To examine
known-group validity, t-tests or analyses of variance
(ANOVA) were performed to examine whether the
MOS-HIV scores differed among participants with vary-
ing sociodemographic and clinical characteristics that
were known to be related to the HRQOL of PLWHA in
a prior review [40]. Statistical analyses were performed
using the IBM SPSS statistical package (version 23.0),
Mplus software (version 7.4), and jMetrik (version 4.0.5).
Results
Sociodemographic and clinical characteristics of
participants
The participants’ characteristics in sociodemographic
and clinical characteristics have been shown in Table 1.
There were missing values (3 to 39) in all variables ex-
cept age. The results of the Little’s missing completely at
random (MCAR) [41] test indicated that the missing
values were MCAR, and thus they did not affect the ana-
lyses (X2 (785) = 50.42, p = 1.00).
The mean age of participants was 48.49 (SD = 13.33)
years. Majority of participants were male (89.1%), not
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Table 1 Participant characteristics (N = 201)
Total Male (n = 179) Female (n = 22)
Variables N (%) or M (SD) N (%) or M (SD) N (%) or M (SD) X2/t p
Sociodemographic variables
Age (n = 201) 48.49 (13.33) 47.35 (13.13) 57.73 (11.41) −3.54 < .001
≤ 40 54 (26.9) 52 (29.1) 2 (9.1) 24.10 < .001
41–60 107 (53.2) 100 (55.9) 7 (31.8)
> 60 40 (19.9) 27 (15.1) 13 (59.1)
Education (n = 197)
Less than high school 45 (22.8) 30 (17.1) 15 (68.2) 30.09 < .001
High school 63 (32.0) 58 (33.1) 5 (22.7)
College or above 89 (45.2) 87 (49.7) 2 (9.1)
Marital status (n = 191)
Not married (single/divorced/widowed) 142 (74.3) 127 (75.1) 15 (68.2) .50 .48
Married 49 (25.7) 42 (24.9) 7 (31.8)
Religion (n = 194)
Yes 106 (54.6) 91 (52.9) 15 (68.2) 1.84 .18
No 88 (45.4) 81 (47.1) 7 (31.8)
Employment (n = 190)
Employed 95 (50.0) 89 (52.7) 6 (28.6) 4.34 < .05
Unemployed 95 (50.0) 80 (47.3) 15 (71.4)
Income (n = 190)
≤ 1 million Korean won (KRW) 65 (34.2) 52 (31.0) 13 (59.1) 7.14 < .05
1–3 million KRWa 70 (36.8) 64 (38.1) 6 (27.3)
3 million KRW 55 (28.9) 52 (31.0) 3 (13.6)
Insurance (n = 176)
National health insurance 117 (66.5) 105 (67.3) 12 (60.0) .43 .52
Medical aid 59 (33.5) 51 (32.7) 8 (40.0)
Clinical variables
CDC Stage (n = 195)
A (Asymptomatic) 67 (34.4) 57 (32.8) 10 (47.6) 2.07 .36
B (Symptomatic) 68 (34.9) 63 (36.2) 5 (23.8)
C (AIDS) 60 (30.8) 54 (31.0) 6 (28.6)
Years since diagnosis (n = 162) 8.26 (5.97) 8.05 (6.06) 10.09 (4.89) −1.34 .18
ART duration (year) (n = 187) 7.09 (5.37) 6.89 (5.54) 8.91 (3.10) −2.44 .02
CD4 cell counts (n = 198) 649.09 (306.96) 642.24 (314.01) 703.91 (242.24) −.89 .38
< 200 cells/ml 9 (4.5) 9 (5.1) 0 (.0) 1.18 .28
≥ 200 cells/ml 189 (95.5) 167 (94.9) 22 (100.0)
HIV RNA log (n = 198)
Not detected 139 (70.2) 123 (69.9) 16 (72.7) .24 .97
< 40 43 (21.7) 39 (22.2) 4 (18.2)
40–2000 9 (4.5) 8 (4.5) 1 (4.5)
> 2000 7 (3.5) 6 (3.4) 1 (4.5)
Psychological comorbidity (n = 198)
Yes 30 (15.2) 25 (14.2) 5 (22.7) 1.11 .29
No 168 (84.8) 151 (85.8) 17 (77.3)
Shim et al. Health and Quality of Life Outcomes  (2018) 16:92 Page 4 of 13
married (74.3%), educated up to college or higher (45.
2%), professed a religion (54.6%), and on the national
health insurance plan (66.5%). In terms of employment
and income status, in general, participants were evenly
distributed across categories.
As for clinical variables, approximately one-third of
the participants were distributed at each of the following
three stages of the Center for Disease Control and Pre-
vention (CDC) classification system: A (asymptomatic),
B (symptomatic), and C (AIDS). The mean for the num-
ber of years since diagnosis was 8.26 (SD = 5.97) years,
and the mean duration of active antiretroviral treatment
(ART) was 7.09 (SD = 5.37) years. The overall HIV-
related condition of the participants was good, with 95.
5% having CD4 cell counts of ≥200 cells/ml, and 70.2%
having HIV RNA log (viral load) not detected. However,
the rate of medical comorbidity was high (91.9%), while
that of psychological comorbidity was 15.2%. Among the
30 participants who had psychological comorbidity, 24
had major depressive disorder, 1 had bipolar I disorder,
3 had insomnia, 1 had snoring/sleep apnea, and 1 had
cognitive dysfunction problems. Additionally, majority of
the participants were infected via sexual transmission,
with 30.6% by heterosexual transmission and 54.1% by
same sex transmission.
The examination of the sociodemographic and clinical
characteristics by sex indicated significant differences be-
tween male and female participants in terms of age, edu-
cation, employment, income, ART duration, and mode
of transmission. Specifically, male participants were
younger, had a higher percentage of college or above
education, and were employed. With reference to in-
come, the overall percentage of an income less than 1
million Korean Won (equivalent to U.S. dollar $872) was
higher among female participants. The mean for the
number of years of ART duration was shorter in male
participants. For mode of transmission, the percentage
of heterosexual transmission was higher among female,
and that of the same sex transmission was higher among
male participants.
Scale properties and internal consistency of the
K-MOS-HIV
The descriptive statistics for the subscale scores and the
data on information for floor and ceiling effects have
been presented in Table 2. The mean scores of the K-
MOS-HIV subscale scores ranged from 53.42 (general
health perception) to 85.87 (social functioning). Further,
while a moderate flooring effect (> 15%) was observed
for the role functioning scores (20.9%), substantial ceil-
ing effects were observed in six subscales scores, espe-
cially for the role functioning (71.1%), social functioning
(63.2%), and pain (48.8%) scores.
The Cronbach’s α of the K-MOS-HIV scales as a meas-
ure of internal consistency, was satisfactory overall, with
values ranging from 0.78 to 0.95 across subscales. Fur-
ther, those for the physical health summary and the
mental health summary were 0.90 and 0.94, respectively.
Construct validity of the K-MOS-HIV: Factorial and
convergent validity
The results of the CFA examining the factorial validity of
the K-MOS-HIV indicated that the proposed two-factor
structures (physical health summary and the mental
health summary) represented by the subscales of the
MOS-HIV showed unsatisfactory goodness of fit indices
(Χ2 (32) = 501.9, p < .001, RMSEA = .270 [.250–.291], CFI
= .608, TLI = .449, and SRMR= 1.367). On the other hand,
the results of the ESEM (Fig. 1), which specified a residual
correlation between general health perception and social
functioning (modification index = 13.65, standardized
expected parameter change = −.34), demonstrated an
adequate fit to the data (Χ2 (25) = 56.2, p < .001, RMSEA
= .079 [.051–.106], CFI = .974, TLI = .953, and SRMR
= .027). While social functioning, role functioning, and
physical functioning loaded on the physical health
summary, mental health, quality of life, energy/fatigue,
health distress, and cognitive functioning loaded on the
mental health summary (Table 3). General health
perception and pain loaded more on the physical health
Table 1 Participant characteristics (N = 201) (Continued)
Total Male (n = 179) Female (n = 22)
Variables N (%) or M (SD) N (%) or M (SD) N (%) or M (SD) X2/t p
Medical comorbidity (n = 198)
Yes 182 (91.9) 164 (93.2) 18 (81.8) 3.40 .07
No 16 (8.1) 12 (6.8) 4 (18.2)
Mode of transmission (n = 196)
Sex with a person of the opposite sex 60 (30.6) 44 (25.3) 16 (72.7) 23.77 < .001
Sex with a person of the same sex 106 (54.1) 104 (59.8) 2 (9.1)
Other 30 (15.3) 26 (14.9) 4 (18.2)
a1–3 million KRW = equivalent to U.S. dollar $872 – $2616
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summary, but it also loaded to a lesser degree on the
mental health summary.
The convergent validity of the K-MOS-HIV was de-
monstrated by its significant positive correlations with
the K-WHOQOL-HIV BREF subscale scores. All
correlations were significant (Table 2) and the correl-
ation coefficients ranged from .22 to .81. Both the physical
and psychological domain scores of the K-WHOQOL-
HIV BREF were significantly correlated with the respective
physical health summary (r = .67, p < .01) and mental
Fig. 1 Standardized estimates in the exploratory structural equation modeling of the K-MOS-HIV (N = 201)
Table 2 Scale properties and internal consistency of the K-MOS-HIV and correlations between K-MOS-HIV and K-WHOQOL-HIV BREF†
K-MOS-HIV
K-WHOQOL-HIV BREF GHP P PF RF SF EF MH HD CF QL HT PHS MHS
Overall QOL .63** .34** .32** .46** .36** .62** .65** .58** .41** .73** .38** .48** .72**
General health .75** .46** .37** .53** .44** .65** .61** .68** .45** .62** .32** .59** .73**
Physical QOL .73** .58** .49** .54** .51** .74** .72** .75** .54** .65** .31** .67** .81**
Psychological QOL .66** .44** .35** .47** .39** .72** .71** .59** .51** .69** .35** .53** .76**
Level of independence .68** .46** .57** .65** .47** .68** .62** .58** .48** .55** .41** .71** .68**
Social relationships .53** .41** .40** .44** .44** .59** .59** .50** .41** .55** .24** .53** .63**
Environment .50** .44** .40** .41** .36** .59** .55** .48** .36** .55** .23** .51** .59**
Spirituality .53** .32** .22** .37** .36** .63** .63** .64** .52** .57** .27** .39** .71**
Range




SD 24.11 20.79 25.11 40.87 22.44 20.50 21.19 27.79 20.67 22.04 19.74
Cronbach’s α 0.88 0.82 0.86 0.90 – 0.78 0.78 0.95 0.89 – – 0.90 0.94
No. of Items 5 2 6 2 1 4 5 4 4 1 1
% Floor 3.0 2.5 0.5 20.9 1.5 1.0 0.5 1.5 0.5 5.0 3.0
% Ceiling 2.5 48.8 33.8 71.1 63.2 3.0 3.5 24.4 25.4 5.5 8.5
GHP General Health Perception, P Pain, PF Physical Functioning, RF Role Functioning, SF Social Functioning, MH Mental Health, EF Energy/Fatigue, HD Health
Distress, CF Cognitive Functioning, QL Quality of Life, HT Health Transition, PHS Physical Health Summary Score, MHS Mental Health Summary Score; **p < .01
† Sample size varies from 193 to 201 due to missing data
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health summary scores (r = .76, p < .01). However, the
correlation of the K-WHOQOL-HIV BREF physical
domain score with the mental health summary of the K-
MOS-HIV (r = .81, p < .01) was slightly stronger as com-
pared to the physical health summary of the K-MOS-HIV.
Results of Rasch analysis
The results of the Rasch analysis have been shown in
Table 4. The data from participants with missing re-
sponses on one or more items were excluded from the
Rasch analysis (n = 16). To evaluate the content homo-
geneity or unidimensionality of the items within each
identified factor, the Rasch measurement model was
used. Following the results of the ESEM supported the
two-factor structure of the K-MOS-HIV, the Rasch ana-
lysis was performed for these two factors.
On the physical health summary, all the items had a
good fit, with the infit MNSQ ranging from 0.69 to 1.37
and outfit MNSQ ranging from 0.50 to 1.37. On the
mental health summary, two items had both infit and
outfit statistics greater than 1.4: the mental health 8b
had an infit of 1.80 and outfit of 2.27; the mental health
8d had an infit of 1.47 and outfit of 1.54. All other items
on the mental health summary demonstrated good fit,
with the infit MNSQ ranging from 0.65 to 1.30 and out-
fit MNSQ ranging from 0.61 to 1.33.
The results regarding item difficulties and the step pa-
rameters for the 34 items indicated that not all items in
all the scales maintain the given step orders. In majority
of the items, only two-step values were not ordered. For
instance, the four step parameters of the item Pain 3
were − 1.44, − 0.68, 1.14, and 0.98, showing that only the
third (1.14) and fourth (0.98) steps were dislocated.
However, six items showed that at least three step esti-
mates were disordered (e.g., − 0.36, − 0.72, − 0.81, 0.87,
and 1.02 for the item Health Distress 9e).
Known-group validity
The results of the t-tests or ANOVAs conducted to
examine the ability of the K-MOS-HIV to detect poten-
tial differences in various dimensions of HRQOL among
participants with different sociodemographic and clinical
characteristics have been summarized in Table 5. In
terms of sociodemographic variables, a number of sub-
scale scores showed significant differences among groups
formed by age, marital status, employment, monthly in-
come and insurance status.
Age was associated with the physical functioning and
social functioning subscales, F (2, 198) = 9.67 and 3.74,
and the physical health summary, F (2, 198) = 5.01. How-
ever, for the social functioning subscale, the post-hoc
analysis revealed that the between-group difference was
not significant. For marital status, the subscale scores on
social functioning, energy/fatigue, and Mental Health as
well as the mental health summary were higher among
married participants than non-married counterparts, t
(189) = 2.24, 2.60, 2.26, and 2.00, respectively. Employed
participants showed higher scores, as compared to their
unemployed counterparts, on eight dimensions of the K-
MOS-HIV (general health perception, physical functio-
ning, role functioning, social functioning, energy/fatigue,
mental health, health distress, and cognitive functioning)
as well as on the two summary scores of physical health
and mental health, t (188) = 2.92, 5.30, 4.11, 2.65, 2.80,
2.40, 2.91, 3.33, 4.29, and 3.09, respectively. Parti-
cipants with higher income showed higher scores than
did those with lower income on all 10 MOS-HIV
subscales and on the physical health summary and
mental health summary, F (2, 187) = 10.00, 5.60, 23.80,
13.17, 4.50, 7.31, 4.78, 5.60, 5.27, 3.24, 19.68, and 6.
63, respectively. Furthermore, the participants on the
national health insurance plan showed a better QOL
than those with medical aid, showing similar patterns
as those observed in employment, t (174) = 3.75, 5.06,
3.50, 3.13, 2.31, 2.17, 2.36, 2.18, 4.87; and 2.50,
respectively.
With reference to the clinical variables, participants
with a CD4 cell count of above 200 cells/ml showed
higher scores on five subscales (general health percep-
tion, physical functioning, role functioning, social func-
tioning, and energy/fatigue) and on the physical health
summary, t (196) = 2.76, 2.30, 2.27, 2.30, 1.99, and 2.91,
respectively. The social functioning scores differed ac-
cording to viral load status (F (3, 194) = 3.07) and ART
duration, t (185) = − 2.52. Additionally, participants with a
shorter ART duration and years since diagnosis showed
higher health transition scores, t (185) = 3.02 and t (160) =
2.85, respectively. Participants with a comorbid psychi-
atric disorder showed lower scores on five subscales (en-
ergy/fatigue, mental health, health distress, cognitive
functioning, and quality of life) and on the mental health
Table 3 Factor loading matrix of the ESEM model (N = 201)
Scales PHS MHS
General health perception .55*** .36**
Pain .38*** .29**
Physical functioning .68*** −.04
Role functioning .71*** −.05
Social functioning .76*** −.04
Energy/Fatigue .15* .76***
Mental health −.10 .99***
Health distress .20** .64***
Cognitive functioning .22* .50***
Quality of life .03 .77***
Factor loading with magnitudes > .35 have been shown in bold; *p < .05,
**p < .01, ***p < .001
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summary, t (196) = − 2.79, − 2.85, − 2.44, − 3.10, − 2.08,
and − 3.12, respectively. Moreover, participants with a
medical comorbidity showed lower scores on three sub-
scales (physical functioning, role functioning, and social
functioning), and on the physical health summary, t (196)
= − 2.04, − 4.63, − 2.19, and − 4.07, respectively.
Discussion
This study examined the reliability and validity of the K-
MOS-HIV in a multicenter study involving 201 outpa-
tients with HIV/AIDS in Korea.
Firstly, ceiling effects were observed in six subscales,
particularly in role functioning (71.1%), social functioning
Table 4 Infit and outfit MNSQ statistics, item difficulties, and step parameters for each item (N = 185)
Item Infit Outfit Diff. Step 1 Step 2 Step 3 Step 4 Step 5
PHS
GHP 1 1.07 1.09 1.68 −3.41 −1.60 1.40 3.61 –
P2 1.37 1.37 −0.87 −1.48 −1.15 0.37 0.63 1.63
P3 0.97 1.04 −1.19 −1.44 −0.68 1.14 0.98 –
PF 4a 1.01 1.04 0.54 −1.12 1.12 – – –
PF 4b 0.84 0.76 − 0.24 − 0.74 0.74 – – –
PF 4c 0.96 1.18 −0.09 − 0.96 0.96 – – –
PF 4d 0.91 0.70 −0.47 − 0.79 0.79 – – –
PF 4e 1.12 0.80 − 0.93 0.20 − 0.20 – – –
PF 4f 1.30 0.83 −1.02 1.45 − 1.45 – – –
RF 5 0.69 0.50 −0.41 – – – – –
RF 6 0.73 0.54 −0.23 – – – – –
SF 7 0.95 0.99 −0.81 0.25 −1.32 −0.51 0.93 0.65
GHP 11a 0.96 0.93 1.06 −2.21 −0.17 −0.23 2.61
GHP 11b 1.19 1.20 1.01 −2.22 −0.43 − 0.66 3.31
GHP 11c 1.05 1.00 1.36 −2.35 −0.40 −0.59 3.34
GHP 11d 1.16 1.27 0.61 −1.82 −0.06 − 0.37 2.25
MHS
MH 8a 0.75 0.66 −0.45 −1.15 − 0.24 −0.34 0.61 1.12
MH 8b 1.80 2.27 0.74 −1.26 −0.79 0.48 −0.14 1.71
MH 8c 0.74 0.75 −0.16 −0.96 − 0.78 −0.57 1.07 1.25
MH 8d 1.47 1.54 0.82 −1.14 −0.81 0.15 0.62 1.18
MH 8e 1.25 1.07 −0.36 − 0.98 −0.59 − 0.05 0.60 1.02
EF 9a 1.13 1.13 0.76 −2.16 −1.16 0.45 1.17 1.69
EF 9b 0.82 0.84 −0.25 −0.77 −0.96 − 0.64 0.72 1.65
EF 9c 0.90 0.92 0.16 −1.60 −1.45 −0.18 1.02 2.21
EF 9d 1.30 1.28 0.59 −1.38 −1.14 0.17 0.94 1.41
HD 9e 0.73 0.73 0.01 −0.36 −0.72 −0.81 0.87 1.02
HD 9f 0.70 0.63 −0.02 − 0.41 −0.70 − 0.48 0.72 0.88
HD 9 g 0.65 0.61 −0.08 −0.44 − 0.33 −0.69 0.93 0.53
HD 9 h 0.91 0.88 0.01 −0.76 − 0.57 −0.31 0.52 1.12
CF 10a 0.79 1.33 −0.28 −0.10 − 0.73 −0.49 0.55 0.77
CF 10b 1.22 1.24 −0.55 −0.52 −1.00 − 0.76 0.91 1.37
CF 10c 0.86 0.78 −0.69 −1.20 −0.19 − 0.79 0.85 1.34
CF 10d 0.93 0.84 −0.93 −0.62 −1.41 − 0.25 1.11 1.17
QL 12 0.82 0.82 0.67 −1.50 −2.17 0.68 3.00 –
GHP General Health Perception, P Pain, PF Physical Functioning, RF Role Functioning, SF Social Functioning, MH Mental Health, EF Energy/Fatigue, HD Health
Distress, CF Cognitive Functioning, QL Quality of Life, PHS Physical Health Summary Score, MHS Mental Health Summary Score
Infit and outfit MNSQ statistics higher than 1.4 or lower than 0.6 as well as disordered step parameters are shown in bold
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(63.2%), and pain (48.8%), while a floor effect was ob-
served in role functioning (20.9%). The observed pattern
of these effects (e.g., ceiling effects for role functioning, so-
cial functioning, and pain) is line with the results obtained
from validation studies of the MOS-HIV in several lan-
guages [16, 19, 42]. For example, ceiling effects in role
functioning (79%), social functioning (76%) and floor ef-
fect in role functioning (14.5%) were reported in the Thai
version of the MOS-HIV [22]. The ceiling effects observed
in the present study might be related to the relatively good
level of HIV-related condition of the participants, as evi-
denced by clinical characteristics such as 95.5% of the par-
ticipants having CD4 cell counts of ≥200 cells/ml and 92%
having an HIV RNA log value less than 40. In fact, major-
ity of the participants in previous studies that reported
similar patterns of ceiling or floor effects had CD4 cell
counts of > 200 cells/ml [19, 42]. On the other hand, floor
effects in social functioning (21.2%) and role functioning
(72.6%) were observed in the Italian version of the MOS-
HIV [20], with only 7.6% of participants having CD4 cell
counts of > 200 cells/ml [20].
Regarding the factorial validity of the K-MOS-HIV, the
results of the ESEM supported its previously proposed
two-factor structure (physical health summary and men-
tal health summary) [27]. However, the loading patterns
of subscales of the physical health summary and mental
health summary were somewhat different. For instance,
in Revicki et al.’s study [27], pain, role functioning, and
physical functioning loaded on the physical health sum-
mary, while mental health, health distress, quality of life
and cognitive functioning loaded on the mental health
summary, and general health perception, social function-
ing and energy/fatigue loaded on both factors. However,
in our study, social functioning loaded on the physical
health summary, and energy/fatigue loaded only on the
mental health summary. Additionally, general health
perception and pain loaded on both factors. In Lau et al.
’ study [16], energy/fatigue loaded on the mental health
summary (factor loading .71) and pain loaded on both
the physical health summary (loading value of .54) and
mental health summary (.26). In the Thai version of the
MOS-HIV [22], while pain loaded mainly on the physical
Table 5 Known-group validity of the K-MOS-HIV†
Scalea, b PHSa, b MHSa, b
GHP P PF RF SF EF MH HD CF QL HT
Sociodemographic variables
Agea *** * **
Sex
Education
Marital statusb ** * * *
Religion
Employmentb ** *** *** ** ** * ** *** *** **
Incomec *** ** *** *** * *** ** ** ** * *** **
Insuranceb *** *** ** ** * * * * *** *
Clinical variables
CDC stage
Years since diagnosisb **
ART durationd * **
CD4 cell countsb ** * * * * **
HIV RNA loge *
Psychological Comorbidityb ** ** * ** * **
Medical Comorbidityb ** *** * ***
Mode of transmission
GHP General Health Perception, P Pain, PF Physical Functioning, RF Role Functioning, SF Social Functioning, MH Mental Health, EF Energy/Fatigue, HD Health
Distress, CF Cognitive Functioning, QL Quality of Life, HT Health Transition; *p < .05, **p < .01, ***p < .001
†Sample size varies from 162 to 201 due to missing data;
aThe post hoc (Bonferroni) tests indicated that PF (1 > 2 = 3) and PHS (1 > 2). 1 = (≤ 40), 2 = (41–60), 3 = (> 60)
bAll results indicate that 1 > 2; 1 =married, 2 = not married; 1 = employed, 2 = unemployed; 1 = National health insurance, 2 =medical aid; 1 = (Years since
diagnosis ≤ mean), 2 = (Years since diagnosis > mean); 1 = (CD4 ≥ 200/mm3), 2 = (CD4 < 200/mm3); 1 = Comorbidity no, 2 = Comorbidity yes
cAll post hoc Bonferroni tests indicated that 1 < 2 = 3, with the exceptions of P (1 < 3) and SF (1 < 2). 1 = (≤ 1 million KRW), 2 = (1–3 million KRW), 3 = (> 3 million KRW)
dSF (1 < 2) and HT (1 > 2). 1 = (ART duration ≤ mean), 2 = (ART duration > mean)
eThe post hoc (Bonferroni) tests indicated that 1 > 2 = 3 = 4; 1 = (Not detected), 2 = (< 40), 3 = (40–2000), 4 = (> 2000)
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health summary (.62), it also loaded on the mental
health summary (.35). The multidimensional nature of
pain [43, 44], as well as the association of pain with
mental health problems previously observed in HIV-
infected adults, [45, 46] might explain this variation.
For instance, the level of anxiety and depression was
higher in patients with HIV reporting pain than in those
who did not [45]. Similarly, HIV+ persons with diagnosed
mood/anxiety and substance use disorders reported sig-
nificantly higher levels of pain than did HIV+ persons
without these comorbid conditions [47]. The loading of
energy/fatigue on the mental health summary may be ex-
plained by a significant association between fatigue and
depression previously observed in PLWHA [48, 49].
Furthermore, an examination of the MNSQ values from
the Rasch analysis showed that the infit and outfit statis-
tics were within acceptable ranges of 0.6–1.4, except for
two items in the mental health summary, indicating the
unidimensionality of the items within each factor.
However, in terms of the step parameter, step disor-
ders were observed in 19 out of 34 items. This might be
a result of the small sample size, and in fact, a sample
size larger than 250 was suggested to ensure an adequate
and stable estimation of parameters for Rasch analysis
[50, 51]. Furthermore, this might be related to the rela-
tively good HIV-related condition of the study partici-
pants, as evidenced by their CD4 cell counts and viral
load status, as well as their scores on K-MOS-HIV.
Eleven out of the 19 items with step disorders were
those which showed ceiling effects. The patterns of step
disorder might be related to the relatively good functioning
level of the participants. A small number of participants
selected the lower level response category. Re-examination
of the K-MOS-HIV with a sufficient number of participants
with varying functioning levels is therefore necessary.
With regard to the known-group validity of the K-
MOS-HIV, a number of subscale scores differed signi-
ficantly across groups with varying sociodemographic (i.
e., age, marital status, employment, monthly income and
insurance) and clinical characteristics (i.e., years since
diagnosis, ART duration, CD4 cell counts, HIV RNA
log, psychological, and medical comorbidity). With re-
gard to sociodemographic variables, younger participants
showed higher physical functioning and physical health
summary scores. This inverse association between age
and physical health observed in the present study is in
line with the findings of a previous review [40]. In a
study with 1191 HIV-positive patients, participants aged
over 45 years reported lower scores on the physical do-
main of the HRQOL than did those aged under 34 years
[52]. Relatedly, a previous study found that nearly half of
older people with HIV had at least one major medical
comorbidity, and a greater burden of co-morbidity was
associated with a lower physical HRQOL [53]. Similarly,
the independent effects of age observed for physical
functioning and general health perceptions, as well as
significant interaction effects of HIV and older age on
daily functioning, were observed in PLWHA [54]. Fur-
ther, in the present study, married people showed higher
social functioning, energy/fatigue, mental health and
mental health summary scores, which might be under-
stood from a previously observed link between social
support and better physical health summary and mental
health summary in PLWHA [40, 55].
The results also suggested that being employed was as-
sociated with an overall higher HRQOL in PLWHA,
which was in line with previous findings [56–58]. In fact,
employment status was the strongest predictor of the
five MOS-HIV health survey subscales scores in
PLWHA in Canada [57]. Similarly, Rueda and colleagues
[56] found that the effect of employment on QOL was
comparable to that of higher HIV-related symptoms.
They also suggested that the association between em-
ployment and QOL is to be understood in both direc-
tions, that is, overall good health being a necessary
prerequisite to get or maintain employment (i.e., “the se-
lection process”), and unemployment status causing
lower QOL (i.e., “the causation process”). Moreover, in-
surance and income showed a similar pattern, which is
in line with previous findings. For instance, lower in-
come was associated with worse physical and mental
health [5], and increased suicide risk [59].
Among clinical variables, there were no significant dif-
ferences in the MOS-HIV scores in terms of CDC stage.
However, as prior studies suggest that the association of
advanced disease with physical health [40] and all the
domains of the MOS-HIV except health transition [60],
the ability of the MOS-HIV to discriminate HRQOL sta-
tus according to the disease stage is unclear. For in-
stance, the Spanish version of the MOS-HIV did not
discriminate well between disease stages [14]. On the
other hand, in a study with the Greek version of the
MOS-HIV, scores on the physical functioning and pain
subscales, and the physical health summary were signifi-
cantly lower in individuals with AIDS compared to those
with asymptomatic HIV+ [19].
Moreover, the present results indicated that the phys-
ical health summary scores as well as those on the sub-
scales that loaded on the physical health summary such
as general health perception, physical functioning, role
functioning, and social functioning were significantly
lower in groups with low CD4 cell counts or the group
with a medical comorbidity. Similarly, the mental health
summary scores as well as those on the subscales com-
prising the mental health summary, such as energy/fatigue
and mental health, were lower in the group with a psycho-
logical comorbidity, confirming the known-group validity
of the MOS-HIV. Although previous findings regarding
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the association between CD4 cell counts and MOH-HIV
scores are mixed, majority of these findings revealed a sig-
nificant association of higher CD4 cell counts with higher
HRQOL [19, 61]. For instance, as compared to those with
CD4 cell counts over 200, the group with CD4 cell counts
less than 200 scored lower on the general health percep-
tion, physical functioning, pain, and energy/fatigue sub-
scales, and the physical health summary in the MOS-HIV
validation study conducted in Taiwan [42]. Similarly, pa-
tients with CD4 cell counts less than 200 showed lower
physical well-being and overall QOL than did those with
CD4 cell counts over 200 [62]. Additionally, in the present
study, social functioning scores differed according to viral
load status, which is partially consistent with a previously
observed negative association of physical and mental
health summary scores with viral loads [63]. The inverse
association of comorbidity burden with overall HRQOL,
particularly with physical QOL, was in line with that ob-
served in previous studies on PLWHA [53, 64]. Further-
more, psychiatric comorbidity was related to lower mental
health summary scores in the present study, which is con-
sistent with previous findings that observed the associ-
ation of depression with diminished HRQOL [60, 65].
The current results should be considered with their
limitations. First, the cross-sectional nature of this study
precludes any causal interpretation regarding the associ-
ations of sociodemographic and clinical characteristics
with several dimensions of the MOS-HIV observed in
this study. Additionally, due to the consecutive sampling
procedure employed, the possibility of sample bias
should be considered, and in fact, the ceiling effects in a
number of subscale scores observed in this study might
be related to the relatively good level of overall HIV-
related health condition of the participants. Those with
a poorer condition were more likely to decline study
participation. However, in terms of sex, age, and mode
of transmission of HIV, the characteristics of our study
participants are similar to those of people living with
HIV/AIDS in South Korea [24]. To explain, 89.1% of our
study participants were male, similar to 92.8% of males
in people living with HIV/AIDS in 2016. In addition, in
our study, 26.9% of the participants were aged below
40 years, 53.2% of them were aged between 41 and
60 years, and 19.9% of them were aged over 60 years, as
compared to the percentages of 38.6, 48.1, and 13.3% re-
ported among PLWHA in South Korea in 2016, respect-
ively [24]. The percentages of heterosexual and same-sex
transmission were 30.6 and 54.1%, respectively, as com-
pared to 58.4 and 41.5%, respectively, which were reported
among notified cases of HIV during 2007–2016 [24].
Moreover, for a HRQOL measure used in clinical prac-
tice, it is necessary to assess the sensitivity of the tool to
detect changes in clinical status over time [66, 67]. How-
ever, the test-retest reliability and the sensitivity of the
K-MOS-HIV to detect changes or responsiveness to
symptom changes [68] was not tested in the present
study, and they should be examined in a longitudinal
and prospective study.
Conclusion
Despite these limitations, the present results suggest that
the K-MOS-HIV is a reliable and valid measure of HRQOL
in PLWHA, which would allow related research as well as
cross-cultural comparisons on HRQOL in this population.
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